KDR and gastric cancer: Similar to other neoplastic diseases, the treatment of GC may benefit from anti-angiogenic drugs including Ramucirumab, a monoclonal antibody antagonist of vascular endothelial growth factor receptor-2 (VEGFR-2), currently used in the second-line therapy of mGC and gastro-esophageal junction carcinomas.